Search - tctmd.com

Displaying 301 - 320 of 367

Sort: Relevancy | Date

News Conference News TCT 2015

SYMPLICITY HTN-3 Results Continue to Spur Discussion

October 11, 2015

News Daily News

Hemodynamic Depression Tied to Kidney Injury After CAS in Patients With Renal Disease

L.A. McKeown

September 28, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation

April 01, 2015

News Daily News

New Percutaneous Device Reduces Resistant Hypertension in Small Trial

February 03, 2015

News Daily News

Year in Review: Physicians Highlight the Most Important Interventional News of 2014

Todd Neale

January 12, 2015

News Daily News

Study Suggests Renal Denervation No More Effective Than Intensified Drug Treatment

Todd Neale

December 10, 2014

News Daily News

Substantial BP Reductions Appear to Lower Stroke Risk Safely in CAD Patients

Todd Neale

November 02, 2014

News Conference News TCT 2014

Symplicity Flex: No Benefit of Renal Denervation in Mild Resistant Hypertension

September 16, 2014

News Industry News

Randomized Sham-Controlled Trial Examines Blood Pressure Effects of Renal Denervation in Patients with Mild Refractory Hypertension

September 16, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation

September 16, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Yael L. Maxwell

September 15, 2014

News Industry News

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

September 13, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation Therapy

September 13, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Yael L. Maxwell

June 11, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

Advertisement

SYMPLICITY HTN-3 Results Continue to Spur Discussion

Hemodynamic Depression Tied to Kidney Injury After CAS in Patients With Renal Disease

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation

New Percutaneous Device Reduces Resistant Hypertension in Small Trial

Year in Review: Physicians Highlight the Most Important Interventional News of 2014

Study Suggests Renal Denervation No More Effective Than Intensified Drug Treatment

Substantial BP Reductions Appear to Lower Stroke Risk Safely in CAD Patients

Symplicity Flex: No Benefit of Renal Denervation in Mild Resistant Hypertension

Randomized Sham-Controlled Trial Examines Blood Pressure Effects of Renal Denervation in Patients with Mild Refractory Hypertension

Experts Debate Future of Renal Denervation

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

Experts Debate Future of Renal Denervation Therapy

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content